CNN
–
Experimental treatment, Gantenerumab, could not help people with a high risk of memory loss from Alzheimer's disease or those who were in the early stages of the disease, the manufacturer said on Monday.
Gantenerumab is part of a class of injection drugs that are designed to remove sticky pieces of protein called the beta -amyloid from the brain. Beta Amyloid Buildup is a distinctive feature of Alzheimer's disease.
Most of these drugs worked in such a way as to clear the beta-amyloid, but many were still unable to demonstrate any real advantages for patients; Their brain function and memory do not improve much, despite treatment.
On Monday, Rosh said that Ganteneramab, according to the visible, removed less than the beta -amyloid from the brain participants, which was supposed. The company said that the results of the phase 3 of his tests called a graduate were difficult, but important for exchange.
“So many of our families suffered directly from Alzheimer's disease, so this news is very disappointed,” said The press is releaseThe field “Despite the fact that the results of the graduates are not the fact that we hoped, we are proud that we delivered a high -quality, clear and comprehensive set of data from Alzheimer's illness to the field, and we are looking forward to the opportunity to share our knowledge with the community, since we continue to look for new methods of treating this complex disease.”
Rosh said that he would share a large number of conclusions from his research at the upcoming medical conference.
The results for Gantenerumab follow positive results for another beta -amyloid drug that reduces, lecanemab. The companies that check this medicine, Biogen and EISAI, announced this year that Lecanemab has slowed down a decrease in the function of the brain in Alzheimer's disease by about 27% compared to placebo. Some experts believe that the degree of benefit is at the level of the scandalous medicine of Alzheimer Audhelm, which was approved by the American food administration and drugs, despite the lack of support from the agency’s independent advisers.
Dr. Konstantin Liquetsos, a psychiatry professor at John Hopkins, said that if Ganteneramab removes as much beta amyloid as the company, this could show the degree of benefit in accordance with Medanemab and Adugelm.
“In other words, a very modest, but not a clinical effect,” said Liquetsos, who did not participate in the study.
The Alzheimer Association stated in her statement that the results of the Rosha study are “disappointed”, but it remains “hopes for this treatment class”.
“Each anti-amyloid treatment, which is tested actions in different ways, and the studies of their effectiveness and safety should continue. It is important to evaluate each treatment on your own, ”said Maria Carrillo, chief researcher at a non-profit organization.
According to the Alzheimer Association, about 6.5 million Americans live with Alzheimer's disease in 2022.
